Mitral regurgitation (MR) is the most common heart valve disorder in the US, with over 4 million individuals affected globally and an incidence of over 250,000 annually. Results of severe MR frequently lead to shortness of breath and fatigue and to potential heart failure and death without treatment. Open heart surgical Mitral valve repair (OHMVR), is the gold-standard option to restore the valve function and patient prognosis. Today minimally-invasive options (transcatheter therapy, TMVR) allow surgeons and interventional cardiologists to perform valvular repairs without opening a patient's chest and represent a safe alternative in a subset of frail patients. The MitralPrint device will be the first endovascular, piezoresistive pressure sensor designed to quantify myocardial contraction fraction (MCF) in real-time during both OHMVR and TMVR allowing the surgeon to record an objective parameter on the MR. This eliminates the need for subjective trans-thoracic ultrasound assessment.
KIN-Therapeutics is developing an AI-based computational platform integrating structural bioinformatics and machine learning with experimental approaches to identify small molecules targeting specific protein kinase targets and conformations. The Kinase Inhibitor (KIN) artificial intelligence (AI) is able to generate de novo kinase drugs with optimal selectivity. This technology will allow for better design and discovery of clinically relevant kinase inhibitors, which will have significant implications for cancer, Alzheimer’s disease, and even diabetes treatments. KIN focuses on a manageable and clinically-relevant chemical space and is entering into a partnership with a biotech company to design conformation specific immune-oncology inhibitors. KIN is looking for a CEO / Chair of the Board to lead the next steps for the venture.